Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial.
Saved in:
| Title: | Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial. |
|---|---|
| Authors: | Janjigian YY; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA. Electronic address: janjigiy@mskcc.org., Kawazoe A; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Hospital East, Kashiwa, Japan., Xu J; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China., Lonardi S; Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Metges JP; CHU Brest-Institut de Cancerologie et d'Hematologie ARPEGO Network, Brest, France., Wyrwicz LS; Department of Oncology and Radiotherapy, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland., Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China., Ostapenko Y; Department of Minimally Invasive and Endoscopic Surgery, National Cancer Institute Ukraine, Kyiv, Ukraine., Bilici M; Atatürk University Faculty of Medicine, Department of Medical Oncology, Erzurum, Türkiye., Lowery MA; Department of Medical Oncology, Trinity St James Cancer Institute, Trinity College, Dublin, Ireland., Valderrama A; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA., Guan Y; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA., Li K; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA., Shih CS; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. |
| Source: | ESMO open [ESMO Open] 2025 Oct; Vol. 10 (10), pp. 105542. Date of Electronic Publication: 2025 Sep 30. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41033280 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Janjigian+YY%22">Janjigian YY</searchLink>; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA. Electronic address: janjigiy@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Kawazoe+A%22">Kawazoe A</searchLink>; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Xu+J%22">Xu J</searchLink>; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Lonardi+S%22">Lonardi S</searchLink>; Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.<br /><searchLink fieldCode="AU" term="%22Metges+JP%22">Metges JP</searchLink>; CHU Brest-Institut de Cancerologie et d'Hematologie ARPEGO Network, Brest, France.<br /><searchLink fieldCode="AU" term="%22Wyrwicz+LS%22">Wyrwicz LS</searchLink>; Department of Oncology and Radiotherapy, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Shen+L%22">Shen L</searchLink>; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Ostapenko+Y%22">Ostapenko Y</searchLink>; Department of Minimally Invasive and Endoscopic Surgery, National Cancer Institute Ukraine, Kyiv, Ukraine.<br /><searchLink fieldCode="AU" term="%22Bilici+M%22">Bilici M</searchLink>; Atatürk University Faculty of Medicine, Department of Medical Oncology, Erzurum, Türkiye.<br /><searchLink fieldCode="AU" term="%22Lowery+MA%22">Lowery MA</searchLink>; Department of Medical Oncology, Trinity St James Cancer Institute, Trinity College, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Valderrama+A%22">Valderrama A</searchLink>; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA.<br /><searchLink fieldCode="AU" term="%22Guan+Y%22">Guan Y</searchLink>; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA.<br /><searchLink fieldCode="AU" term="%22Li+K%22">Li K</searchLink>; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA.<br /><searchLink fieldCode="AU" term="%22Shih+CS%22">Shih CS</searchLink>; Department of Medical Oncology, Merck & Co. Inc., Rahway, USA.<br /><searchLink fieldCode="AU" term="%22Rha+SY%22">Rha SY</searchLink>; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101690685%22">ESMO open</searchLink> [ESMO Open] 2025 Oct; Vol. 10 (10), pp. 105542. <i>Date of Electronic Publication: </i>2025 Sep 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101690685 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-7029 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220597029%22">20597029 </searchLink><i>NLM ISO Abbreviation: </i>ESMO Open <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41033280 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.esmoop.2025.105542 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 105542 Titles: – TitleFull: Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Janjigian YY – PersonEntity: Name: NameFull: Kawazoe A – PersonEntity: Name: NameFull: Xu J – PersonEntity: Name: NameFull: Lonardi S – PersonEntity: Name: NameFull: Metges JP – PersonEntity: Name: NameFull: Wyrwicz LS – PersonEntity: Name: NameFull: Shen L – PersonEntity: Name: NameFull: Ostapenko Y – PersonEntity: Name: NameFull: Bilici M – PersonEntity: Name: NameFull: Lowery MA – PersonEntity: Name: NameFull: Valderrama A – PersonEntity: Name: NameFull: Guan Y – PersonEntity: Name: NameFull: Li K – PersonEntity: Name: NameFull: Shih CS – PersonEntity: Name: NameFull: Rha SY IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2025 Oct Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2059-7029 Numbering: – Type: volume Value: 10 – Type: issue Value: 10 Titles: – TitleFull: ESMO open Type: main |
| ResultId | 1 |
